This week Dr. Durie answers the question "How does the new flow cytometry testing for MRD compare to molecular testing?"

Dr. Brian G.M. Durie is the Chairman of the Board of Directors of the International Myeloma Foundation. He began studying multiple myeloma over 30 years ago, and is recognized around the world as one of the top myeloma doctors.

Previous Post
#AskDrDurie: Are clinical trials part of the BSRI(R), and if so, how can I participate?
Next Post
China update: renewed friendships and new collaborations

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.